NZ625391A - Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors - Google Patents

Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors

Info

Publication number
NZ625391A
NZ625391A NZ625391A NZ62539110A NZ625391A NZ 625391 A NZ625391 A NZ 625391A NZ 625391 A NZ625391 A NZ 625391A NZ 62539110 A NZ62539110 A NZ 62539110A NZ 625391 A NZ625391 A NZ 625391A
Authority
NZ
New Zealand
Prior art keywords
ngf
antibody
neutralizing antibodies
human anti
subcutaneous injection
Prior art date
Application number
NZ625391A
Other languages
English (en)
Inventor
James J S Treanor
Frank Martin
Kenneth D Wild
Haichun Huang
Heather Inoue
Tie J Zhang
Original Assignee
Amgen Inc
Medarex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43466840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ625391(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc, Medarex Llc filed Critical Amgen Inc
Publication of NZ625391A publication Critical patent/NZ625391A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03F—PHOTOMECHANICAL PRODUCTION OF TEXTURED OR PATTERNED SURFACES, e.g. FOR PRINTING, FOR PROCESSING OF SEMICONDUCTOR DEVICES; MATERIALS THEREFOR; ORIGINALS THEREFOR; APPARATUS SPECIALLY ADAPTED THEREFOR
    • G03F7/00—Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printing surfaces; Materials therefor, e.g. comprising photoresists; Apparatus specially adapted therefor
    • G03F7/004—Photosensitive materials
    • G03F7/09—Photosensitive materials characterised by structural details, e.g. supports, auxiliary layers
    • G03F7/091—Photosensitive materials characterised by structural details, e.g. supports, auxiliary layers characterised by antireflection means or light filtering or absorbing means, e.g. anti-halation, contrast enhancement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
NZ625391A 2009-10-09 2010-10-08 Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors NZ625391A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/576,522 US9260514B2 (en) 2003-07-15 2009-10-09 Methods of treating conditions caused by increased expression of nerve growth factor (NGF) or increased sensitivity to NGF using anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
NZ599431A NZ599431A (en) 2009-10-09 2010-10-08 Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors

Publications (1)

Publication Number Publication Date
NZ625391A true NZ625391A (en) 2016-02-26

Family

ID=43466840

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ625391A NZ625391A (en) 2009-10-09 2010-10-08 Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
NZ599431A NZ599431A (en) 2009-10-09 2010-10-08 Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ599431A NZ599431A (en) 2009-10-09 2010-10-08 Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors

Country Status (28)

Country Link
US (1) US9260514B2 (enExample)
EP (2) EP3028717A1 (enExample)
JP (3) JP2013507385A (enExample)
KR (1) KR101528393B1 (enExample)
CN (1) CN102762228A (enExample)
AR (1) AR078569A1 (enExample)
AU (2) AU2010308418A1 (enExample)
BR (1) BR112012008282A2 (enExample)
CA (1) CA2775924A1 (enExample)
CL (1) CL2012000881A1 (enExample)
CO (1) CO6541558A2 (enExample)
CR (1) CR20120198A (enExample)
EA (1) EA201290189A1 (enExample)
IL (1) IL218885A0 (enExample)
MA (1) MA33724B1 (enExample)
ME (1) ME00226B (enExample)
MT (1) MTP4289B (enExample)
MX (1) MX343748B (enExample)
MY (1) MY172283A (enExample)
NZ (2) NZ625391A (enExample)
PE (1) PE20121028A1 (enExample)
PH (1) PH12012500668A1 (enExample)
SG (1) SG10201603945RA (enExample)
TN (1) TN2012000136A1 (enExample)
TW (1) TW201125581A (enExample)
UA (1) UA102775C2 (enExample)
WO (1) WO2011049758A1 (enExample)
ZA (1) ZA201203135B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
NZ596839A (en) * 2009-05-04 2014-01-31 Abbott Res Bv Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
BR112016009862B1 (pt) * 2013-11-29 2021-12-21 Genentech, Inc Método de fabricação de uma composição
US11202606B2 (en) 2015-04-17 2021-12-21 Koninklijke Philips N.V. Detection of anisotropic biological tissue
EA201991283A9 (ru) 2016-11-29 2019-11-27 Фармацевтическая композиция для предотвращения опиоидной зависимости
EP3765516A2 (en) * 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
KR20210043624A (ko) * 2018-08-10 2021-04-21 리제너론 파아마슈티컬스, 인크. 무릎 및/또는 고관절 통증의 안전하고 효과적인 치료를 위한 약제학적 조성물
IT201800009384A1 (it) 2018-10-11 2020-04-11 Cosmo Srl Peptide for cosmetic application
WO2020248942A1 (zh) * 2019-06-10 2020-12-17 山东博安生物技术有限公司 抗β-NGF纳米抗体及其应用
CN117050175B (zh) * 2020-04-17 2024-07-16 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN113549150A (zh) * 2020-04-26 2021-10-26 三生国健药业（上海）股份有限公司 结合人ngf的抗体、其制备方法和用途
US20230220057A1 (en) * 2020-05-27 2023-07-13 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof
AU2020204105B2 (en) * 2020-06-19 2023-06-08 Dartsbio Pharmaceuticals Ltd. Anti-human ngf antibodies and methods using same
US11655292B2 (en) 2020-06-23 2023-05-23 Ampsource Biopharma Shanghai Inc. Anti-human NGF antibodies and methods using same
IT202000020287A1 (it) * 2020-08-20 2022-02-20 Colosseum Combinatorial Chemistry Centre For Tech Societa A Responsabilita Limitata In Forma Abbrevi Peptide per applicazioni terapeutiche in campo dermatologico
EP4433500A1 (en) 2021-11-19 2024-09-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
UY40122A (es) * 2022-01-21 2023-08-15 Pralonir S A S Inmunización activa para reducir el dolor osteoarticular, neuropático y en cáncer
EP4514849A1 (en) 2022-04-27 2025-03-05 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist
FR3148027A1 (fr) * 2023-04-24 2024-10-25 Peptinov Composition vaccinale anti-ngf

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US913242A (en) 1905-08-29 1909-02-23 Electrelle Company Automatic music-playing attachment for pianos.
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4230691A (en) 1978-05-23 1980-10-28 The Massachusetts General Hospital Nerve growth factor antibody and process
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4710473A (en) 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4786593A (en) 1985-04-16 1988-11-22 Wistar Institute Of Anatomy And Biology Diagnostic method for detection of neural crest disease
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
JP2969647B2 (ja) 1988-09-14 1999-11-02 東ソー株式会社 モノクローナル抗体、それからなる阻害剤及びそれを用いた測定方法
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE465573B (sv) 1989-03-14 1991-09-30 Lope Medicine Ab Nervtillvaextfaktorpeptider, motsvarande antikroppar och foerfarande foer bestaemning av nativ nervtillvaextfaktor
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
EP0418590B1 (en) 1989-08-28 1997-11-19 Takeda Chemical Industries, Ltd. Antibodies, production thereof and use
JPH03163095A (ja) 1989-08-28 1991-07-15 Takeda Chem Ind Ltd ヒト神経成長因子の部分ペプチド、抗体およびその用途
US5656435A (en) 1989-08-28 1997-08-12 Takeda Chemical Industries, Ltd. Antibodies to peptides having NGF-like activity, said antibodies having no substantial cross-reactivity with NGF, and use thereof
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP3232415B2 (ja) 1990-08-29 2001-11-26 武田薬品工業株式会社 モノクローナル抗体，その製造法および用途
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JPH06317587A (ja) 1990-08-31 1994-11-15 Takeda Chem Ind Ltd 抗体およびその用途
US5147294A (en) 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
WO1992022646A1 (en) 1991-06-14 1992-12-23 Dnx Corp. Production of human hemoglobin in transgenic pigs
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
JPH0576384A (ja) 1991-09-20 1993-03-30 Hitachi Ltd 抗ヒト神経成長因子モノクローナル抗体
JP3519096B2 (ja) 1992-07-02 2004-04-12 武田薬品工業株式会社 モノクローナル抗体、ハイブリドーマおよびそれらの用途
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
GB9616105D0 (en) 1996-07-31 1996-09-11 Univ Kingston TrkA binding site of NGF
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
PL218748B1 (pl) 1999-03-25 2015-01-30 Abbott Gmbh & Co Kg Wyizolowane przeciwciało ludzkie lub jego część wiążąca antygen, zawierająca je kompozycja farmaceutyczna, sposób hamowania aktywności ludzkiej IL-12 in vitro, zastosowanie przeciwciała lub jego części wiążącej antygen, sposób wykrywania ludzkiej IL-12, wyizolowana cząsteczka kwasu nukleinowego, zrekombinowany wektor ekspresyjny, komórka gospodarz oraz sposób syntetyzowania ludzkiego przeciwciała lub jego części wiążącej antygen
CA2380813A1 (en) 1999-07-29 2001-02-08 Medarex, Inc. Human monoclonal antibodies to her2/neu
EP2110138A1 (en) 1999-08-27 2009-10-21 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
CN1684708A (zh) 2001-05-30 2005-10-19 基因技术股份有限公司 抗ngf抗体用于治疗各种疾病
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
EP1369431A4 (en) 2001-10-15 2005-01-12 Kirin Brewery ANTI-HLA-DR ANTIBODIES
EP1467756A4 (en) 2001-12-28 2007-03-21 Abgenix Inc METHODS OF USING ANTI-MUC18 ANTIBODIES
US6919426B2 (en) * 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
ZA200502612B (en) 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
SI2263692T1 (sl) 2002-12-24 2020-10-30 Rinat Neuroscience Corp. Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CN102358903B (zh) 2003-07-15 2017-04-26 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
KR100894191B1 (ko) * 2003-07-15 2009-04-22 암젠 인코포레이티드 선택적인 ｎｇｆ 경로 저해제로서의 인체 항-ｎｇｆ 중화 항체 및 이 항체를 포함하는 약학적 조성물
RU2406728C2 (ru) 2005-01-24 2010-12-20 Медиммун Лимитэд Партнеры специфического связывания с ngf
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
CA2775924A1 (en) 2011-04-28
PE20121028A1 (es) 2012-08-06
CR20120198A (es) 2012-07-30
AR078569A1 (es) 2011-11-16
NZ599431A (en) 2014-07-25
EP2485760B1 (en) 2016-07-13
KR101528393B1 (ko) 2015-06-11
JP2014169326A (ja) 2014-09-18
KR20120117007A (ko) 2012-10-23
AU2014203316B2 (en) 2016-07-07
ME00226B (me) 2011-02-10
AU2014203316A1 (en) 2014-07-10
PH12012500668A1 (en) 2017-05-10
EP3028717A1 (en) 2016-06-08
MX343748B (es) 2016-11-22
WO2011049758A1 (en) 2011-04-28
TN2012000136A1 (en) 2013-09-19
US9260514B2 (en) 2016-02-16
EP2485760A1 (en) 2012-08-15
IL218885A0 (en) 2012-06-28
BR112012008282A2 (pt) 2016-11-22
CL2012000881A1 (es) 2013-02-08
MX2012004035A (es) 2012-05-08
ZA201203135B (en) 2013-01-30
CO6541558A2 (es) 2012-10-16
SG10201603945RA (en) 2016-07-28
EA201290189A1 (ru) 2012-10-30
JP2013507385A (ja) 2013-03-04
CN102762228A (zh) 2012-10-31
MY172283A (en) 2019-11-20
UA102775C2 (uk) 2013-08-12
MTP4289B (en) 2011-05-12
JP2017014286A (ja) 2017-01-19
MA33724B1 (fr) 2012-11-01
TW201125581A (en) 2011-08-01
AU2010308418A1 (en) 2012-05-10
US20100034818A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
NZ625391A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
NZ611878A (en) Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
HRP20191162T1 (hr) Postupci liječenja ankilozantnog spondilitisa uporabom anti-il-17 protutijela
JP2014169326A5 (enExample)
IN2012DN02826A (enExample)
MX2018006844A (es) Composicion para tratar la diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada.
MY188825A (en) High-concentration monoclonal antibody formulations
MX366314B (es) Uso de derivados de insulina por inyecciones con intervalos variables.
NZ597666A (en) Combination therapy of an afucosylated cd20 antibody with bendamustine
NZ596739A (en) Methods of treating proliferative diseases
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
NZ595767A (en) Composition for the treatment of prostate cancer
RU2014146170A (ru) Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX392388B (es) Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe)
WO2012079093A3 (en) Dosage and administration of bispecific scfv conjugates
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
RU2015112121A (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
MX2015007402A (es) Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos.
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
WO2011006084A3 (en) Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof
RU2007141393A (ru) Способ лечения спастического и болевого синдромов у пациентов с последствиями позвоночно-спинномозговой травмы
NZ707246A (en) Uses of Bremelanotide in Therapy for Female Sexual Dysfunction
NZ775405B2 (en) Humanized antibodies against c-kit

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: E. R. SQUIBB + SONS, L.L.C., US

Effective date: 20160331

Owner name: AMGEN INC., US

Effective date: 20160331

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 OCT 2017 BY AJ PARK

Effective date: 20160819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2018 BY CPA GLOBAL

Effective date: 20170831

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2019 BY CPA GLOBAL

Effective date: 20180830

LAPS Patent lapsed